Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 13;4(9):e0762.
doi: 10.1097/CCE.0000000000000762. eCollection 2022 Sep.

Risk Factors and Clinical Outcomes of Candidemia Associated With Severe COVID-19

Deepali Dixit  1 , Polly Jen  2 , Tyler D Maxwell  3 , Steven Smoke  4 , James Andrew McCracken  1 , Maria Cardinale-King  1 , Aditi Haribhakti  1 , Purvi Patel  5 , Eris Cani  3 , Seohyun Claudia Choi  6 , Sugeet Jagpal  7 , Tilly Varughese  5 , Luis L Tatem  8 , Tanaya Bhowmick  5
Affiliations

Risk Factors and Clinical Outcomes of Candidemia Associated With Severe COVID-19

Deepali Dixit et al. Crit Care Explor. .

Abstract

COVID-19 can cause serious illness requiring multimodal treatment and is associated with secondary infections. Studies have suggested an increased risk of fungal infections, including candidemia following severe COVID-19 though understanding of risk factors and clinical outcomes remains unclear.

Objectives: To describe clinical characteristics, outcomes and risk factors of candidemia among patients hospitalized with severe COVID-19.

Design setting and participants: A multicenter, case-control study of patients with severe COVID-19 was conducted to evaluate risk factors and clinical outcomes in patients who developed candidemia between August 2020 and August 2021.

Main outcomes and measures: Chart review evaluating institutional and patient demographics, clinical and mycological characteristics, concomitant interventions (antibiotics, immunosuppressive agents, parenteral nutrition, degree of oxygen support, mechanical ventilation, surgery), treatment regimens, and outcomes (length of stay and discharge disposition).

Results: A total of 275 patients were enrolled in the study, including 91 patients with severe COVID-19 and subsequent candidemia and 184 with severe COVID-19 without candidemia. Most patients received antibiotics prior to candidemia episode (93%), while approximately one-quarter of patients received biologic for COVID-19. In-hospital mortality was significantly higher in the cases compared with the controls (68% vs 40%; p < 0.01). Candida albicans was the most common (53%), followed by C. glabrata (19%). Use of central lines, biologic, and paralytics were independent risk factors for candidemia.

Conclusions and relevance: Candidemia following COVID-19 infection is a concern that requires clinical consideration and patient monitoring. Risk factors for the development of candidemia in the setting of COVID-19 infection are largely consistent with traditional risk factors for candidemia in hospitalized patients.

Keywords: COVID-19; candidemia; co-infection; severe acute respiratory syndrome coronavirus 2 infection.

PubMed Disclaimer

Conflict of interest statement

Dr. Dixit is the primary author; she was awarded an investigator sponsored grant provided by Astellas. The remaining authors have disclosed that they do not have any potential conflicts of interest.

References

    1. Johns Hopkins University of Medicine: Coronavirus Resource Center. 2021. Available at: coronavirus.jhu.edu. Accessed March 31, 2022
    1. National Institutes of Health: COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available at: https://www.covid19treatmentguidelines.nih.gov/. Accessed March 20, 2022 - PubMed
    1. Russell CD, Fairfield CJ, Drake TM, et al. ; ISARIC4C investigators: Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: A multicentre, prospective cohort study. Lancet Microbe 2021; 2:e354–e365 - PMC - PubMed
    1. Langford BJ, So M, Raybardhan S, et al. : Bacterial co-infection and secondary infection in patients with COVID-19: A living rapid review and meta-analysis. Clin Microbiol Infect 2020; 26:1622–1629 - PMC - PubMed
    1. Goncalves Mendes Neto A, Lo KB, Wattoo A, et al. : Bacterial infections and patterns of antibiotic use in patients with COVID-19. J Med Virol 2021; 93:1489–1495 - PMC - PubMed